Thymogen
Also known as: Glu-Trp, Glutamyl-tryptophan
Overview
Thymogen is a synthetic dipeptide (Glu-Trp) bioregulator derived from the thymus and representing another member of the Khavinson peptide family. It combines glutamic acid and tryptophan to provide immunomodulatory effects primarily targeting T-lymphocyte function. Research suggests it modulates T-cell differentiation, balances cytokine profiles, and may have applications in immune deficiency states associated with aging, chronic illness, or post-chemotherapy recovery.
Mechanism of Action
Thymogen (Glu-Trp) acts as a chromatin-modulating dipeptide similar to Vilon, interacting with DNA-associated proteins to regulate gene expression in immune cells. It influences T-helper cell polarization and cytokine production, potentially through NF-κB pathway modulation similar to other Khavinson peptides. The tryptophan component may additionally influence serotonin and kynurenine pathways that modulate immune tolerance and inflammation.
Potential Benefits
- T-lymphocyte function modulation
- Cytokine balance improvement in immunodeficiency
- Potential recovery support post-chemotherapy
- Anti-inflammatory effects via NF-κB pathway modulation
- Thymus function support in aging
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Beginner | 100 mcg daily for 5 days |
| Intermediate | 100 mcg daily for 10 days |
| Advanced | 100 mcg daily for 10 days, repeat every 3-6 months |
| Cycle Duration | 5-10 day cycles |
Khavinson dipeptide (Glu-Trp). Thymic immune bioregulator approved in Russia.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Subcutaneous Injection High
Standard route.
Intranasal Moderate
Russian-approved intranasal formulation available.
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving Thymogen:
Immune Support Stack
Layered thymic-immune support for immunocompromised or aging immune systems.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Storage | Refrigerate at 2-8°C after reconstitution. Do not freeze reconstituted solution. |
|---|
Typical vial sizes: 1-5 mg. Add bac water slowly down the side of the vial, swirl gently — do not shake. Use insulin syringe for precise dosing.
Need exact syringe measurements?
Amino Acid Sequence
Glu-Trp
Side Effects & Safety
- Generally well-tolerated
- Minimal reported adverse effects
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Pregnancy / Lactation
Bleeding Disorders
Active Skin Infection at Injection Site
Pharmacokinetics
| Half-Life | Not well characterized for this peptide; consult primary literature |
|---|---|
| Storage | Store lyophilized peptide at -20°C (long-term) or 2-8°C (short-term, under 30 days). Reconstituted: refrigerate at 2-8°C and use within 28-30 days. Protect from light. Do not freeze reconstituted solution. |
Synergistic Compounds
The following compounds have been studied alongside Thymogen for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
FDA Staff Reviewers Say ‘No’ to 7 Compounded Peptides Ahead of July PCAC Vote
FDA staff reviewers urged against adding seven popular peptides to the 503A bulks list ahead of the July PCAC meeting, citing weak human data and safety uncertainty.
FDA reviewers urge ‘no’ on BPC-157, TB-500, MOTS-c ahead of July 2026 compounding vote
FDA reviewers’ June 29 briefings recommend against listing seven popular peptides for 503A compounding, citing limited human data and immunogenicity risk.
Medicare Starts Paying for Obesity Drugs Today — Bridge Program Opens $50 Access for Millions
Medicare's new $50 Bridge program covering Wegovy, Zepbound, Foundayo, and oral Wegovy for obesity launched July 1 — the first Medicare weight-loss benefit.
FDA staff urges caution on compounded peptides ahead of July advisory meeting
Ahead of the July 23–24 Pharmacy Compounding Advisory Committee meeting, FDA staff briefings recommend against listing seven popular peptides for compounding.